共 64 条
[1]
Bombardier C(2000)VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 1520-1528
[2]
Laine L(2002)The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors Arthritis Rheum 47 349-355
[3]
Reicin A(2004)Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations Aliment Pharmacol Ther 20 48-58
[4]
Strand V(1998)The risk game Reliability, Engineering, and System Safety 59 73-77
[5]
Hochberg MC(1991)Risk perception of prescription drugs: report on a survey in Canada Can J Public Health 82 515-520
[6]
Lazzaroni M(1987)Perception of Risk Science 236 280-285
[7]
Bianchi Porro G(2000)Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 1247-1255
[8]
Slovic P(2004)Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity Arthritis Rheum 50 1734-1739
[9]
Slovic P(2002)Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac Am J Cardiol 89 425-430
[10]
Kraus N(2001)Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib Circulation 104 2280-2288